Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

OBJECTIVE: To assess efficacy and safety of lixisenatide monotherapy in type 2 diabetes. RESEARCH DESIGN AND METHODS: Randomized, double-blind, 12-week study of 361 patients not on glucose-lowering therapy (HbA(1c) 7–10%) allocated to one of four once-daily subcutaneous dose increase regimens: lixis...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Fonseca, Vivian A., Alvarado-Ruiz, Ricardo, Raccah, Denis, Boka, Gabor, Miossec, Patrick, Gerich, John E.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2012
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3357248/
https://ncbi.nlm.nih.gov/pubmed/22432104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc11-1935
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky